[
    [
        {
            "time": "2023-10-17",
            "original_text": "科創板、創業板迎大批醫藥潛力股",
            "features": {
                "keywords": [
                    "科創板",
                    "創業板",
                    "醫藥潛力股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫藥",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "科創板、創業板迎大批醫藥潛力股",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "A股醫藥二十年深度復盤：從普漲到分化 看醫藥行情如何契合政策主線",
            "features": {
                "keywords": [
                    "A股",
                    "醫藥",
                    "政策主線",
                    "普漲",
                    "分化"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股醫藥二十年深度復盤：從普漲到分化 看醫藥行情如何契合政策主線",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "【異動股】人腦工程板塊下挫，西藏藥業(600211-CN)跌停",
            "features": {
                "keywords": [
                    "人腦工程",
                    "西藏藥業",
                    "跌停"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "醫藥",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【異動股】人腦工程板塊下挫，西藏藥業(600211-CN)跌停",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "逾10家藥企擬分拆子公司上市，涉及診斷試劑、疫苗等板塊",
            "features": {
                "keywords": [
                    "藥企",
                    "分拆",
                    "子公司",
                    "上市",
                    "診斷試劑",
                    "疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫藥",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "逾10家藥企擬分拆子公司上市，涉及診斷試劑、疫苗等板塊",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "逾10家藥企擬分拆子公司上市 涉及診斷試劑、疫苗等板塊",
            "features": {
                "keywords": [
                    "藥企",
                    "分拆",
                    "子公司",
                    "上市",
                    "診斷試劑",
                    "疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫藥",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "逾10家藥企擬分拆子公司上市 涉及診斷試劑、疫苗等板塊",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]